Literature DB >> 29705879

Tumor fragmentation estimated by volume surface ratio of tumors measured on 18F-FDG PET/CT is an independent prognostic factor of diffuse large B-cell lymphoma.

Pierre Decazes1,2, Stéphanie Becker3,4, Mathieu Nessim Toledano3,4, Pierre Vera3,4, Paul Desbordes3,4, Fabrice Jardin5,6, Hervé Tilly5,6, Isabelle Gardin3,4.   

Abstract

INTRODUCTION: Our aim was to study the prognostic value of two new 18F-FDG PET biomarkers in diffuse large B-cell lymphoma (DLBCL). We examined the total tumor surface (TTS), describing the tumor-host interface, and the tumor volume surface ratio (TVSR), corresponding to the ratio between the total metabolic tumor volume (TMTV) and TTS, describing the tumor fragmentation.
METHODS: We retrospectively included 215 patients with DLBCL. Patients underwent initial 18F-FDG PET/CT before R-CHOP (73%) or intensified R-CHOP (R-ACVBP) regimens (27%). The TMTV was measured using a fixed threshold value of 41% of SUVmax. To calculate TTS and TVSR, the surface was measured using an in-house software based on the marching cube algorithm. Spearman's rank correlation coefficient (ρ) was computed between TMTV, TTS, and TVSR, and ROC analysis was performed. Survival functions at 5 years were studied using a Kaplan-Meier method and uni/multivariate Cox analysis.
RESULTS: TVSR was poorly correlated with TMTV (ρ = 0.5) and TTS (ρ = 0.26), while TTS was highly correlated with TMTV (ρ = 0.94) and was, therefore, excluded from the analysis. TMTV had the highest area under the ROC curve (0.711) and the best sensitivity (0.797), while TVSR had the best specificity (0.745). The optimal cut-off values to predict 5-year OS were 222 cm3 for TMTV and 6.0 mm for TVSR. Patients with high TMTV and TVSR had significantly worse prognosis in Kaplan-Meier and Cox univariate analysis. In a multivariate Cox analysis combining the International Prognostic Index (IPI), the type of chemotherapy, TMTV, and TVSR, all parameters were independent and significant prognostic factors (HR [95%CI]: IPI 1.4 [1.1-1.8], type of chemotherapy 4.5 [2.0-10.5], TMTV 2.8 [1.4-5.5], TVSR 2.1 [1.3-3.4]). A synergistic effect between TMTV and TVSR was observed in a Kaplan-Meier analysis combining the two parameters.
CONCLUSIONS: TVSR measured on the initial 18F-FDG PET is an independent prognostic factor in DLBCL and has an additional prognostic value when combined with TMTV, IPI score and chemotherapy.

Entities:  

Keywords:  Diffuse; Fluorodeoxyglucose F18; Large B-Cell; Lymphoma; Positron emission tomography; factor; prognostic; tumor burden; tumor-host interface

Mesh:

Substances:

Year:  2018        PMID: 29705879     DOI: 10.1007/s00259-018-4041-0

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  26 in total

1.  Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  H Tilly; M Gomes da Silva; U Vitolo; A Jack; M Meignan; A Lopez-Guillermo; J Walewski; M André; P W Johnson; M Pfreundschuh; M Ladetto
Journal:  Ann Oncol       Date:  2015-09       Impact factor: 32.976

2.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

3.  Association between textural and morphological tumor indices on baseline PET-CT and early metabolic response on interim PET-CT in bulky malignant lymphomas.

Authors:  Fayçal Ben Bouallègue; Yassine Al Tabaa; Marilyne Kafrouni; Guillaume Cartron; Fabien Vauchot; Denis Mariano-Goulart
Journal:  Med Phys       Date:  2017-08-02       Impact factor: 4.071

4.  Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients.

Authors:  Michel Meignan; Myriam Sasanelli; René Olivier Casasnovas; Stefano Luminari; Federica Fioroni; Chiara Coriani; Helene Masset; Emmanuel Itti; Paolo G Gobbi; Francesco Merli; Annibale Versari
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-26       Impact factor: 9.236

5.  Prognostic Value of Metabolic Tumor Volume Estimated by (18) F-FDG Positron Emission Tomography/Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma of Stage II or III Disease.

Authors:  Jihyun Kim; Junshik Hong; Seog Gyun Kim; Kyung Hoon Hwang; Minsu Kim; Hee Kyung Ahn; Sun Jin Sym; Jinny Park; Eun Kyung Cho; Dong Bok Shin; Jae Hoon Lee
Journal:  Nucl Med Mol Imaging       Date:  2014-05-29

6.  Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma.

Authors:  Anne-Ségolène Cottereau; Hélène Lanic; Sylvain Mareschal; Michel Meignan; Pierre Vera; Hervé Tilly; Fabrice Jardin; Stéphanie Becker
Journal:  Clin Cancer Res       Date:  2016-03-02       Impact factor: 12.531

7.  Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement.

Authors:  Moo-Kon Song; Joo-Seop Chung; Ho-Jin Shin; Sang-Min Lee; Su-Ee Lee; Ho-Sup Lee; Gyeong-Won Lee; Seong-Jang Kim; Seok-Mo Lee; Dong-Seop Chung
Journal:  Ann Hematol       Date:  2011-11-11       Impact factor: 3.673

Review 8.  FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas.

Authors:  Sally F Barrington; Regine Kluge
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-04-14       Impact factor: 9.236

9.  Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma.

Authors:  Hajira Ilyas; N George Mikhaeel; Joel T Dunn; Fareen Rahman; Henrik Møller; Daniel Smith; Sally F Barrington
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-19       Impact factor: 9.236

10.  PET-CT for Evaluation of Spleen and Liver 18F-FDG Diffuse Uptake Without Lymph Node Enlargement in Lymphoma.

Authors:  Liangjun Rao; Xiaoyan Wang; Zhen Zong; Zhifeng Chen; Xinchong Shi; Chang Yi; Xiangsong Zhang; Zhiyun Yang
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889

View more
  9 in total

1.  Discovery of Pre-Treatment FDG PET/CT-Derived Radiomics-Based Models for Predicting Outcome in Diffuse Large B-Cell Lymphoma.

Authors:  Russell Frood; Matthew Clark; Cathy Burton; Charalampos Tsoumpas; Alejandro F Frangi; Fergus Gleeson; Chirag Patel; Andrew F Scarsbrook
Journal:  Cancers (Basel)       Date:  2022-03-28       Impact factor: 6.639

2.  Comparing lesion and feature selections to predict progression in newly diagnosed DLBCL patients with FDG PET/CT radiomics features.

Authors:  Jakoba J Eertink; Gerben J C Zwezerijnen; Matthijs C F Cysouw; Sanne E Wiegers; Elisabeth A G Pfaehler; Pieternella J Lugtenburg; Bronno van der Holt; Otto S Hoekstra; Henrica C W de Vet; Josée M Zijlstra; Ronald Boellaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-08-04       Impact factor: 10.057

Review 3.  Predicting cancer outcomes with radiomics and artificial intelligence in radiology.

Authors:  Kaustav Bera; Nathaniel Braman; Amit Gupta; Vamsidhar Velcheti; Anant Madabhushi
Journal:  Nat Rev Clin Oncol       Date:  2021-10-18       Impact factor: 65.011

4.  A prognostic model integrating PET-derived metrics and image texture analyses with clinical risk factors from GOYA.

Authors:  Lale Kostakoglu; Federico Dalmasso; Paola Berchialla; Larry A Pierce; Umberto Vitolo; Maurizio Martelli; Laurie H Sehn; Marek Trněný; Tina G Nielsen; Christopher R Bolen; Deniz Sahin; Calvin Lee; Tarec Christoffer El-Galaly; Federico Mattiello; Paul E Kinahan; Stephane Chauvie
Journal:  EJHaem       Date:  2022-03-24

5.  Fully automatic segmentation of diffuse large B cell lymphoma lesions on 3D FDG-PET/CT for total metabolic tumour volume prediction using a convolutional neural network.

Authors:  Paul Blanc-Durand; Simon Jégou; Salim Kanoun; Alina Berriolo-Riedinger; Caroline Bodet-Milin; Françoise Kraeber-Bodéré; Thomas Carlier; Steven Le Gouill; René-Olivier Casasnovas; Michel Meignan; Emmanuel Itti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-10-24       Impact factor: 9.236

6.  Automated quantification of baseline imaging PET metrics on FDG PET/CT images of pediatric Hodgkin lymphoma patients.

Authors:  Amy J Weisman; Jihyun Kim; Inki Lee; Kathleen M McCarten; Sandy Kessel; Cindy L Schwartz; Kara M Kelly; Robert Jeraj; Steve Y Cho; Tyler J Bradshaw
Journal:  EJNMMI Phys       Date:  2020-12-14

7.  Gross Tumor Volume Definition and Comparative Assessment for Esophageal Squamous Cell Carcinoma From 3D 18F-FDG PET/CT by Deep Learning-Based Method.

Authors:  Yaoting Yue; Nan Li; Husnain Shahid; Dongsheng Bi; Xin Liu; Shaoli Song; Dean Ta
Journal:  Front Oncol       Date:  2022-03-17       Impact factor: 6.244

8.  Convolutional Neural Networks for Automated PET/CT Detection of Diseased Lymph Node Burden in Patients with Lymphoma.

Authors:  Amy J Weisman; Minnie W Kieler; Scott B Perlman; Martin Hutchings; Robert Jeraj; Lale Kostakoglu; Tyler J Bradshaw
Journal:  Radiol Artif Intell       Date:  2020-09-02

9.  Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review.

Authors:  R Frood; C Burton; C Tsoumpas; A F Frangi; F Gleeson; C Patel; A Scarsbrook
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-02-18       Impact factor: 9.236

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.